AGC Pharma Chemicals will attend BOS Manchester 2025, one of the key meetings for the biopharma and CDMO sectors in Europe, with the objective of reaffirming its position as a global provider of small-molecule development and manufacturing, including APIs, HPAPIs and intermediates. The company will be located at Stand 17, where it will showcase its integrated capabilities and extensive high-level manufacturing expertise.
With more than four decades of experience in the CDMO business, AGC Pharma Chemicals offers solutions that cover the entire lifecycle of an active ingredient, from development through to commercial production. This participation strengthens our European expansion strategy and ongoing capacity growth, aligned with the recent inauguration of our advanced facility in Malgrat de Mar (Barcelona), representing a 30% increase in production capacity.
At Stand 17, attendees will be able to learn first-hand about:
- Our portfolio of end-to-end services and specialized technologies, including complex reactions and fluorination, as well as capabilities ranging from gram to ton scale.
- A fully integrated CDMO approach, covering the entire process from early-stage development to regulated production, with cGMP compliance and extensive experience in international inspections.
- A firm commitment to quality, process flexibility, and supply assurance—key pillars of our value proposition.
The pharmaceutical industry requires, now more than ever, partners that combine agility, reliability, and technical excellence. AGC Pharma Chemicals addresses these needs through a robust infrastructure, cutting-edge technology, and a highly specialized team. At BOS Manchester 2025, we will be ready to engage with partners and clients, discuss ongoing and future projects, identify synergies, and explore pathways toward more efficient, future-ready pharmaceutical manufacturing.
We invite you to schedule a meeting with us at Stand 17, where you will have the opportunity to explore our approach, capabilities, and collaborative vision.
